NX-1607, a small molecule inhibitor of CBL-B, is efficacious as a single agent and in combination with Rituximab in preclinical mouse models of lymphoma
Monday, September 25, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix has reported that NX-1607, a small molecule inhibitor of CBL-B, demonstrates efficacy both as a standalone treatment and in combination with Rituximab in preclinical models of lymphoma. This advancement highlights the potential of NX-1607 in targeting cancer and autoimmune diseases. The results from mouse models suggest a significant therapeutic promise.
Price reaction · baseline $8.85 (2023-09-22 close) · hit pre-market · 3 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-4.2%
Market Sentiment Analysis
POSITIVE FACTORS
NX-1607 shows efficacy as a single agent.
Combination with Rituximab enhances treatment potential.
Preclinical results indicate promising outcomes in lymphoma models.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-1607?
NX-1607 is a small molecule inhibitor of CBL-B developed by Nurix.
How does NX-1607 work in lymphoma?
NX-1607 shows efficacy as a single agent and in combination with Rituximab.
What are the results of NX-1607 in preclinical models?
Preclinical mouse models indicate promising outcomes for NX-1607 in lymphoma.
What is the significance of CBL-B inhibition?
Inhibiting CBL-B may enhance immune responses against cancer.